Abstract
Most solid tumors are insensitive to single-agent immunotherapy, calling for the development of combinatorial treatment regimens. Recently, Lin and collaborators developed a pharmacological platform enabling the combination of different immunotherapies into a single chemical entity. This approach may effectively circumvent obstacles associated with the simultaneous delivery of multiple immunotherapeutic agents.
| Original language | English |
|---|---|
| Pages (from-to) | 95-97 |
| Number of pages | 3 |
| Journal | Trends in Pharmacological Sciences |
| Volume | 46 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2025 |
Keywords
- CD8 cytotoxic T lymphocyte
- dendritic cell
- immune checkpoint inhibitor
- immunoevasion
- multimodal targeting chimera
- triple orthogonal linker
- Neoplasms/therapy
- Animals
- Immunotherapy/methods
- Humans
- Combined Modality Therapy
Fingerprint
Dive into the research topics of 'A novel pharmacological entity toward integrated multimodal immunotherapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver